ImmunityBio Drug Gets FDA Nod - Los Angeles Business Journal

Published on 29 Apr 2024 on Los Angeles Business Journal

Approval clears way for distribution.

Read the rest of the article

Start tracking your investments with Statfolio

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated...

Benzinga · via AOL 25 Oct 2024

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated...

Benzinga · via Yahoo Finance 23 Oct 2024

We recently compiled a list of the 10 Best Fast-Growing Penny Stocks to Buy Now. In this article,...

Insider Monkey · via Yahoo Finance 21 Sep 2024

ImmunityBio’s IBRX commercial portfolio comprises its only marketed drug, Anktiva (N-803, or noga...

Zacks · via Yahoo Finance 20 Jun 2024

Mullen Automotive, Inc. MULN shares are trading higher Monday after the company announced the Cal...

Benzinga 29 Apr 2024

Super Micro Computer, Inc. SMCI shares are trading higher Monday, and the stock is up more than 2...

Benzinga 29 Apr 2024

Approval clears way for distribution.

Los Angeles Business Journal 29 Apr 2024

On Monday, ImmunityBio Inc (NASDAQ:IBRX) saw its price target increased by Piper Sandler from $5....

Investing.com 29 Apr 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.40%

Investing.com 26 Apr 2024

ImmunityBio, Inc. IBRX shares are trading higher Friday after the company announced overall survi...

Benzinga 26 Apr 2024